STOCKS TELEGRAPH

Tag: TBIO STOCK PRICE

  • Telesis Bio (TBIO) Stock Soars In Pre-Market After Strategic Partnership

    Telesis Bio (TBIO) Stock Soars In Pre-Market After Strategic Partnership

    Shares of Telesis Bio, Inc. (NASDAQ: TBIO) are soaring on the US stock charts today, following the announcement of a significant partnership. In pre-market trading, TBIO stock surged 105.60% as of the latest check, reaching a value of $4.77. This rise reflects the market’s positive response to the new collaboration between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation.

    Telesis Partnered to Drive Scalable Biofoundries

    The collaboration between Telesis Bio and Beckman Coulter Life Sciences aims to develop highly efficient and scalable biofoundries. These biofoundries will facilitate sustainable and rapid on-premises DNA synthesis using Telesis Bio’s Gibson SOLA enzymatic reagent platform.

    Combining this cutting-edge platform with the automated technology of Beckman Coulter allows for the scalable, dependable, and quick manufacture of high-fidelity DNA. It is anticipated that the collaboration would greatly improve researchers’ capacity to make breakthroughs in a variety of discovery applications.

    TBIO On Path To Flexibility And Innovation In Synthetic Biology

    A key aspect of the collaboration is the integration of Gibson SOLA Enzymatic Synthesis with Beckman Coulter’s Biomek Echo One System, an advanced automation tool. This integration offers an open and flexible solution, allowing researchers to incorporate constructs from other providers compatible with Gibson SOLA technology.

    This capability enhances the technology’s flexibility and broadens its applications in synthesizing unique and complex biological structures. Telesis Bio’s partnership is poised to revolutionize synthetic biology, enabling the creation of local DNA foundries that function as digital-to-biologic converters. These biofoundries can deliver DNA or mRNA at an unprecedented speed, potentially as fast as overnight.

    Advancing Therapeutic And Diagnostic Discoveries

    For Beckman Coulter, this collaboration aligns with its mission to be a trusted laboratory partner by facilitating breakthrough research through more efficient and accurate processes. The Biomek Echo One System streamlines critical workflows such as DNA extraction, fragmentation, and ligation, bringing new levels of automation to DNA and mRNA synthesis.

    This partnership represents a pivotal moment in the advancement of synthetic biology, setting a new standard for on-premises biofoundries and fostering the next wave of therapeutic and diagnostic innovations.

  • Translate Bio Inc. (TBIO) stock is plummeting 22%, Here’s what you should know

    Translate Bio Inc. (TBIO) stock is plummeting 22%, Here’s what you should know

    The Translate Bio Inc. (TBIO) stock lost 22.10% in the pre-market trading on Thursday, March 18 2021 after TBIO announced the clinical trial results of its RNA drug. The negativity continuous in the pre-market session as of this writing and it lost a further 25.10%.

    TBIO shared the news with the market yesterday March 17, 2021, and according to the results RNA drug failed to improve lung function in cystic fibrosis patients and the news sent TBIO stock plummeting.

    Although no adverse reaction was noted except mild to moderate symptoms of a febrile reaction such as fever, headache and chills occurred in three patients after the first dose of MRT5005 and it didn’t improve lung function.

    Translate Bio Chief Medical Officer Ann Barbieris still hopeful and said that based on the first and second interim analyses. TBIO stock has achieved a safety profile that supports repeat dosing of inhaled mRNA and further advancement of the pulmonary platform for chronic dosing.

    Cystic fibrosis is the most common fatal inherited disease in the United States, affecting more than 30,000 patients in the U.S. and more than 70,000 patients worldwide.

    COVID-19 Vaccine update

    On March 15, 2021, Translate Bio and its partner Sanofi showed their initiation of a phase I/II study on their mRNA-based vaccine candidate, MRT5500, to check the vaccine’s safety & immune response. Companies are looking to enroll 415 adults. Trial data is expected to be available in the third quarter of 2021.

    Granting non-qualified stock options

    On March 3, 2021, TBIO stock told that it has granted non-qualified stock options to purchase an aggregate of 54,250 shares, for $23.80 per share of TBIO’s common stock to seven newly hired employees.

    About TBIO

    TBIO is developing a revolutionary class of potential medicines, based on mRNA, to treat or prevent debilitating or life-threatening diseases. TBIO was founded in 2001 and its headquarter is in Lexington, Massachusetts, United States. TBIO  has its own mRNA therapeutic platform (MRT) and is using to treat pulmonary diseases caused by insufficient protein production or where the production of proteins can modify disease.